Ouro Fino Saude Animal Participacoes SA 2022 AR2
The report highlights Ourofino Group's performance in 2022, marking its 10th sustainability report and second integrated report. The company surpassed BRL 1 billion in revenue for the first time, representing a 68% growth from 2020 to 2022. Key achievements include welcoming Mitsui as a shareholder, establishing an ESG Committee, and achieving 100% renewable energy at its Cravinhos site. Additionally, Ourofino completed its first M&A with the biotechnology startup Regenera to commercialize stem cell therapy for dogs.
Company: Ouro Fino Saude Animal Participacoes SA
Sector: Manufacturing
Country: Brazil
Year: 2022
Type: AR2
Pages: 180
Back to company
Ouro Fino Saude Animal Participacoes SA
Annual Report
The report highlights Ourofino Group's performance in 2022, marking its 10th sustainability report and second integrated report. The company surpassed BRL 1 billion in revenue for the first time, representing a 68% growth from 2020 to 2022. Key achievements include welcoming Mitsui as a shareholder, establishing an ESG Committee, and achieving 100% renewable energy at its Cravinhos site. Additionally, Ourofino completed its first M&A with the biotechnology startup Regenera to commercialize stem cell therapy for dogs.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees